Clinical effects of roxadustat versus recombinant human erythropoietin in treatment of maintenance hemodialysis patients with renal anemia

LIU Pengcheng

doi:10.7619/jcmp.20244955

Journal of Clinical Medicine in Practice > 2024 > 28(24): 121-123, 128. > DOI: 10.7619/jcmp.20244955

LIU Pengcheng. Clinical effects of roxadustat versus recombinant human erythropoietin in treatment of maintenance hemodialysis patients with renal anemia[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 121-123, 128. DOI: 10.7619/jcmp.20244955

Citation:

PDF (660 KB)

Clinical effects of roxadustat versus recombinant human erythropoietin in treatment of maintenance hemodialysis patients with renal anemia

LIU Pengcheng

Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, 225009

More Information

Received Date: October 20, 2024
Revised Date: November 14, 2024

Graphical Abstract

Abstract

Abstract

Objective
To compare the clinical effects of roxadustat and recombinant human erythropoietin (rHuEPO) in treatment of maintenance hemodialysis patients with renal anemia.
Methods
From January 2021 to December 2023, 100 patients with renal anemia undergoing maintenance hemodialysis admitted to Northern Jiangsu People's Hospital Affiliated to Yangzhou University were selected as study subjects. Based on different treatment approaches, they were divided into control group (n=50) and observation group (n=50). Both groups received iron supplementation therapy, with the control group using recombinant human erythropoietin (rHuEPO) and the observation group using roxadustat. Anemia indicators, iron metabolism indicators, and the incidence of adverse reactions were observed and compared between the two groups.
Results
Before treatment, there was no statistically significant difference in the indicators between the two groups (P>0.05). After treatment, the indicators of both groups improved compared to before treatment, and the indicators of the observation group were superior to those of the control group (P < 0.05). The incidence of adverse reactions in the observation group was 2.00%, which was lower than 16.00% in the control group (P < 0.05).
Conclusion
Compared with rHuEPO, roxadustat can significantly improve anemia and iron metabolism, with high safety and application value.
- roxadustat,
- recombinant human erythropoietin,
- maintenance hemodialysis,
- renal anemia,
- iron metabolism,
- adverse reactions

FullText(HTML)

References (16)

References

[1]	ERIKSSON D, GOLDSMITH D, TEITSSON S, et al. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia[J]. BMC Nephrol, 2016, 17(1): 97. doi: 10.1186/s12882-016-0312-9
[2]	HOSHINO J, MUENZ D, ZEE J, et al. Associations of hemoglobin levels with health-related quality of life, physical activity, and clinical outcomes in persons with stage 3-5 nondialysis CKD[J]. J Ren Nutr, 2020, 30(5): 404-414. doi: 10.1053/j.jrn.2019.11.003
[3]	THORP M L, JOHNSON E S, YANG X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease[J]. Nephrology, 2009, 14(2): 240-246. doi: 10.1111/j.1440-1797.2008.01065.x
[4]	ZOPPINI G, TARGHER G, CHONCHOL M, et al. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients[J]. Atherosclerosis, 2010, 210(2): 575-580. doi: 10.1016/j.atherosclerosis.2009.12.008
[5]	杨洁, 边宇, 张蕊. 非透析慢性肾脏病患者发生肾性贫血风险预测模型的开发与验证[J]. 实用临床医药杂志, 2023, 27(10): 72-78. doi: 10.7619/jcmp.20230125
[6]	张姣姣, 郭松佳, 罗琰琨. 维持性血液透析患者促红细胞生成素抵抗机制及治疗的研究进展[J]. 中国医药, 2021, 16(7): 1108-1112.
[7]	程红娟, 魏芝薇, 史慧, 等. 罗沙司他治疗维持性血液透析患者难治性肾性贫血的疗效观察[J]. 实用临床医药杂志, 2021, 25(14): 75-77, 83. doi: 10.7619/jcmp.20211178
[8]	中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502. doi: 10.3760/cma.j.cn112137-20210201-00309
[9]	LI Y, SHI H, WANG W M, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: first multicenter, cross-sectional study[J]. Medicine, 2016, 95(24): e3872. doi: 10.1097/MD.0000000000003872
[10]	成水芹, 周婷婷, 张志宏, 等. 罗沙司他和重组人促红细胞生成素对腹膜透析患者血压及心脑血管并发症的影响[J]. 肾脏病与透析肾移植杂志, 2022, 31(1): 9-14.
[11]	KOULOURIDIS I, ALFAYEZ M, TRIKALINOS T A, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis[J]. Am J Kidney Dis, 2013, 61(1): 44-56. doi: 10.1053/j.ajkd.2012.07.014
[12]	LOCATELLI F, DEL VECCHIO L, NICOLA L D, et al. Are all erythropoiesis-stimulating agents created equal[J]. Nephrol Dial Transplant, 2021, 36(8): 1369-1377. doi: 10.1093/ndt/gfaa034
[13]	MAXWELL P H, ECKARDT K U. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond[J]. Nat Rev Nephrol, 2016, 12(3): 157-168. http://www.xueshufan.com/publication/2191103386
[14]	程琼, 曾小玲, 陈彦仁, 等. 罗沙司他与重组人促红素治疗非透析肾性贫血的效果及铁稳态对比分析[J]. 北方药学, 2021, 18(12): 136-138.
[15]	宋陆茜, 常春康. 铁代谢、铁评估指标和补铁治疗策略[J]. 中国血液净化, 2020, 19(3): 157-160.
[16]	张蓬杰, 荀利如, 丁通, 等. 应用罗沙司他与重组人促红素治疗的初始血液透析肾性贫血患者的临床疗效及安全性分析[J]. 临床肾脏病杂志, 2022, 22(11): 917-923.

Cited By

Cited by

Periodical cited type(1)

郑执一，曹鹏飞，陈文奇，王锐，乔建龙，邵花香，李华玲. ANGPTL4的作用及机制. 生命的化学. 2024(05): 890-899 .

Other cited types(3)

Get Citation

PDF

XML

Article views (75) PDF downloads (9) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

Clinical effects of roxadustat versus recombinant human erythropoietin in treatment of maintenance hemodialysis patients with renal anemia

Abstract

References

Cited by

Periodical cited type(1)

Other cited types(3)

Catalog

Export File

Citation

Format

Content